Thursday, December 29, 2022

Antiviral treatments lead to the rapid accrual of hundreds of SARS-CoV-2 mutations in immunocompromised patients

 

Within days of treatment, we detected a large number of low-frequency mutations in patients and that these new mutations could persist and, in some cases, were fixed in the virus population … This commonly used class of antivirals has the capability to supercharge SARS-CoV-2 evolution, and uncontrolled use may generate new variants with a transmission advantage that prolongs the pandemic and makes other therapeutics less effective.

https://www.medrxiv.org/content/10.1101/2022.12.21.22283811v1

No comments: